TrialNet's Work to Prevent Type 1 Diabetes: Moving Research Toward Real Options

TrialNet is a research network focused on understanding and preventing Type 1 diabetes. The organization, along with other research groups, is working to develop therapies that could prevent or delay the onset of Type 1 diabetes in at-risk individuals and those newly diagnosed.

For nearly a century, Type 1 diabetes treatment has centered on insulin replacement. Researchers at TrialNet believe prevention research is moving the field toward an important shift: offering newly diagnosed patients interventions beyond insulin therapy.

According to Dr. Michael Haller, a researcher involved in this work, the field is reaching a point where prevention may transition from purely academic research to practical clinical options for patients.

As prevention research advances, the potential exists to tell newly diagnosed patients about treatment options that could delay or prevent further disease progression. This represents a meaningful expansion of what clinicians can offer beyond current standard care.

These studies are ongoing, and researchers continue to refine and improve prevention approaches. The goal is to make prevention a real therapy available to those at risk or recently diagnosed with Type 1 diabetes.

Source: YouTube community video. Evidence type: Community video — lay discussion, not peer-reviewed research. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.